The maker of a promising ovarian cancer drug said, Friday, that he stopped enrolling women in a study because several patients developed gastrointestinal holes.
The study initially enrolled 1,500 women.
( z1 enroll :ARG0 ( z2 study ) :ARG1 ( z3 woman :quant 1500 ) :time ( z4 initial ) )